dr. hamid on tmb as a biomarker for immunotherapy response in melanoma
Published 4 years ago • 209 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
1:19
dr. hamid on using biomarkers for immunotherapy in melanoma
-
1:05
dr. hamid on immune therapy in melanoma
-
0:55
dr. hamid on patient selection for immunotherapy regimens in melanoma
-
1:13
dr. hamid on immunotherapy approaches in melanoma
-
6:55
tmb and immunotherapy in advanced nsclc
-
2:32
dr. hamid on a retrospective analysis of pembrolizumab in melanoma
-
2:53
opacin-neo: tmb and ifn-γ identified as biomarkers of pathologic response in melanoma
-
3:18
tmb as a predictive biomarker in nsclc
-
1:25
tumor mutational burden (tmb): a predictive biomarker for lung cancer immunotherapy response
-
1:32
dr. hamid on melanoma as a therapeutic driver for other cancers
-
2:21
dr. omid hamid on vemurafenib and atezolizumab in melanoma
-
11:06
esmo 2019: dr. hamid discusses exciting immunotherapy data in melanoma
-
1:50
dr. hamid on epacadostat plus pembrolizumab in advanced melanoma
-
2:08
dr. hamid on exciting phase iii trials in melanoma
-
1:48
dr. hamid discusses treating melanoma
-
2:00
dr. blank on predictive biomarkers in macroscopic stage iii melanoma
-
4:20
blood and tissue tmb in predicting response to immunotherapy
-
1:08
dr. hamid on the effectiveness of immunotherapy in aya patients with melanoma
-
1:43
dr. topalian on biomarkers for anti- pd-1 therapies in melanoma